Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CARD-024 (1α-Hydroxy-Vitamin-D5) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs 1-alpha-hydroxyvitamin-D5 (Primary)
- Indications Cardiovascular disorders; Kidney disorders
- Focus Therapeutic Use
- Sponsors Cardiavent
- 29 May 2015 New trial record